AR and metastatic prostate carcinoma: A study showed that a transcriptional profile detectable in CTCs obtained from liquid biopsies can serve as an independent prognostic marker beyond AR-V7 in patients with metastatic prostate cancer and can be used to identify the emergence of multiple androgen receptor signaling inhibitors (ARSIs) resistance mechanisms [25].